The DEFINITY® Illuminate Series

See VALUE in

High DEF(INITY)™

The DEFINITY® Illuminate Series is designed to increase quality and efficiency, reduce costs, enhance diagnostic accuracy, and improve adherence to UEA guidelines^1-4

Through the DEFINITY® Illuminate Series, Lantheus provides you with institutional and educational value presentations, webinars, and an operational efficiencies toolkit. They aim to:

Drive clinical and diagnostic value across stakeholders

Deliver clinical and technical support

Support the efficient implementation of DEFINITY® across clinical settings

Optimize DEFINITY® images

Help to integrate UEA policy

Help echo lab with sonographer administration of DEFINITY®

CLINICAL SPECIALIST PROGRAMS

clinical specialist programs

See SUPPORT in High DEF(INITY)™

Dedicated on-site clinical and technical support delivered by expert sonographers to assist with the efficient implementation of DEFINITY®.*

SPEAKERS PROGRAMS

Speaker Programs

See EXPERTISE in High DEF(INITY)™

Physicians and sonographers share their knowledge and experience on the diagnostic and clinical impact of DEFINITY® on echocardiograms in speaker program presentations.*

NURSE PROGRAMS

Nurse Programs

See CARING in High DEF(INITY)™

Presentations that address nursing staff needs on the safety and efficacy of DEFINITY® and the overall impact it has on patient care.^†

These programs fulfill a need for structured teaching opportunities for non-reading clinicians, which benefits both patient care and interspecialty collaboration⁵

PHYSICIAN ROUNDTABLES

Physician Roundtable

See CONNECTIONS in High DEF(INITY)™

Physician-to-physician forums where HCPs can connect and share how UEAs impact the diagnostic capability of echocardiography.

IMPROVE PROGRAM

Improve Program

See IMPACT in High DEF(INITY)™

Designed to enhance echocardiography by identifying suboptimal echo rates and to illustrate the clinical and economic benefits that can be achieved with appropriate use of DEFINITY®. This quality improvement program helps participants:

Define and quantify the challenge and impact of suboptimal echo
Recognize the important role that DEFINITY® has in improving diagnostic quality, cardiac diagnosis, and patient management^2,3
Identify costs of using DEFINITY® for patients with suboptimal echoes compared to the cost of other imaging modalities and related expenses associated with the need for additional downstream diagnostic procedures^2,3
Evaluate the clinical and economic benefits that are possible with the appropriate use of DEFINITY®^2-4
Initiate a quality echo program that will better serve their patients and their institution

INFORMATIONAL WEBINARS

Informational Webinars

See KNOWLEDGE in High DEF(INITY)™

Live and on-demand webinars designed to provide timely and important information on the use, implementation, and impact DEFINITY® has on cardiac diagnosis, patient management, and cost-effectiveness in echocardiography.* Topics include:

Cardiac diagnosis and patient management
Case study review
Contrast echo in critical care
DEFINITY® across multiple care settings
DEFINITY® implementation and administration
DEFINITY® safety profile

Guidelines and standards
Image optimization
Improving patient outcomes
Optimizing the value of DEFINITY®
Quality-driven echocardiography
Workflow efficiency

OPERATIONAL TOOL KIT

Operational Tool kit

See GUIDANCE in High DEF(INITY)™

A detailed guide to help implement DEFINITY® in your institution, including a summary of American Society of Echocardiography (ASE) Guidelines, discussion framework for roles and responsibilities for optimizing DEFINITY® use, and detailed instructions and troubleshooting tools.

* Society of Diagnostic Medical Sonography (SDMS) credits are available for sonographers who enroll in these programs.

^† American Association of Critical-Care Nurses (AACN) credits are available for nurses who enroll in these programs.

UEA=ultrasound enhancing agent

Annually, Lantheus educates ~10,000 HCPs through >1000 programs. A majority of the programs provide SDMS and AACN credits.¹

INDICATIONS

DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

INDICATIONS

CONTRAINDICATIONS

DEFINITY® is contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG) [see Warnings and Precautions (5.2) and Description (11)].

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

In postmarketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren and PEG-containing microsphere administration [see Adverse Reactions (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions and/or with pre-existing PEG hypersensitivity [see Adverse Reactions (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying conditions.

Patients with sickle cell disease may be at higher risk of painful crisis and DEFINITY® should be administered with caution.

Please see accompanying full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

References:

Data on file, Lantheus.
Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810. doi:10.1016/j.jacc.2009.01.005
Main ML, Fu JW, Gundrum J, LaPointe NA, Gillam LD, Mulvagh SL. Impact of contrast echocardiography on outcomes in critically ill patients. Am J Cardiol. 2021;150:117-122. doi:10.1016/j.amjcard.2021.03.039
Lester SJ, Askew JW, Hurst RT, et al. Contrast echocardiography: experience in a clinical echocardiography laboratory. J Am Soc Echocardiogr. 2006;19(7):919-923. doi:10.1016/j.echo.2006.01.025
Ayesa SL, Katelaris AG, Brennan PC, Grieve SM. Medical imaging education opportunities for junior doctors and non-radiologist clinicians: a review. J Med Imaging Radiat Oncol. 2021;65(6):710-718. doi:10.1111/1754-9485.13266

Customer Service 1.800.299.3431

BACK TO
TOP